{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:27:35Z","timestamp":1791829655593,"version":"4.3.4"},"reference-count":99,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This evidence\u2010 and consensus\u2010based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength\/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.<\/jats:p>","DOI":"10.1111\/jdv.16915","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T13:14:36Z","timestamp":1608642876000},"page":"2461-2498","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":398,"title":["EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 1: treatment and monitoring recommendations"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-2203","authenticated-orcid":false,"given":"A.","family":"Nast","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin Berlin Institute of Health Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.I.","family":"Spuls","sequence":"additional","affiliation":[{"name":"Academic Medical Centre Amsterdam Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Avila Valle","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin Berlin Institute of Health Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Bata\u2010Cs\u00f6rg\u00f6","sequence":"additional","affiliation":[{"name":"University of Szeged Szeged Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Boonen","sequence":"additional","affiliation":[{"name":"Office\u2010Based Dermatology Practice Geel Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De Jong","sequence":"additional","affiliation":[{"name":"Radboud University medical centre Nijmegen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Garcia\u2010Doval","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Fundaci\u00f3n Piel Sana AEDV Madrid Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gisondi","sequence":"additional","affiliation":[{"name":"University of Verona Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kaur\u2010Knudsen","sequence":"additional","affiliation":[{"name":"University hospital Copenhagen K\u00f8benhavn Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mahil","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"M\u00e4lk\u00f6nen","sequence":"additional","affiliation":[{"name":"Helsinki University Central Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Maul","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Z\u00fcrich Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mburu","sequence":"additional","affiliation":[{"name":"International Federation of Psoriasis Associations (IFPA)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Schleswig\u2010Holstein Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Reich","sequence":"additional","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Remenyik","sequence":"additional","affiliation":[{"name":"University of Debrecen Debrecen Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"R\u00f8nholt","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital Aarhus N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Sator","sequence":"additional","affiliation":[{"name":"Municipal Hospital Hietzing Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmitt\u2010Egenolf","sequence":"additional","affiliation":[{"name":"Dermatology Department of Public Health &amp; Clinical Medicine Ume\u00e5 University Ume\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sikora","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Warsaw Warszawa Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Str\u00f6mer","sequence":"additional","affiliation":[{"name":"Office\u2010Based Dermatology Practice M\u00f6nchengladbach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Sundnes","sequence":"additional","affiliation":[{"name":"Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Trigos","sequence":"additional","affiliation":[{"name":"International Federation of Psoriasis Associations (IFPA)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Van Der Kraaij","sequence":"additional","affiliation":[{"name":"Academic Medical Centre Amsterdam Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yawalkar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital Bern University Hospital University of Bern Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dressler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin Berlin Institute of Health Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"e_1_2_13_2_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2011"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04576.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886310666151014115532"},{"key":"e_1_2_13_5_1","first-page":"2","volume-title":"Position Statement of biosimilars \u2010 IFPA","author":"International Federation of Psoriasis Association","year":"2019"},{"key":"e_1_2_13_6_1","volume-title":"IFPA Advocacy Toolkit for UNIVERSAL HEALTH COVERAGE","author":"International Federation of Psoriasis Association","year":"2019"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07405.x"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.008"},{"key":"e_1_2_13_9_1","volume-title":"Burden of Disease in Psoriasis and Psoriatic Arthritis. Occurrence, Healthcare Use, Costs and Health Outcome.","author":"L\u00f6fvendahl S","year":"2016"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"issue":"62","key":"e_1_2_13_13_1","first-page":"50","article-title":"Clinical meaning of change in Dermatology Life Quality Index scores","volume":"147","author":"Khilji FA","year":"2002","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000119415"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07817.x"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13542"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14454"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12118"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","article-title":"Treatment goals for psoriasis: Should PASI 90 become the standard of care?","volume":"106","author":"Torres T","year":"2015","journal-title":"Actas dermo\u2010sifiliograficas"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18333"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.9.1175"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15920"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.78"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04244-5"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15864"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2941"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011"},{"key":"e_1_2_13_31_1","unstructured":"The GRADE Working Group. Vol. 2018.2018."},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13995"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13957"},{"key":"e_1_2_13_34_1","first-page":"Cd011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"1","author":"Sbidian E","year":"2020","journal-title":"Cochrane Database System Rev"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14114"},{"key":"e_1_2_13_37_1","first-page":"35","article-title":"A double\u2010blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study","volume":"69","author":"Kragballe K","year":"1989","journal-title":"Acta dermato\u2010venereologica"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6712"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17198"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15340"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.01.003"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.11.002"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3398-3"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70069-6"},{"key":"e_1_2_13_46_1","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","author":"Ortiz Z","year":"2000","journal-title":"Cochrane Database System Rev"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12312"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1265"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03263.x"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345623"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23835"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802441234"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14072"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282fcc345"},{"key":"e_1_2_13_58_1","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti\u2010tumor necrosis factor: a large retrospective study","volume":"34","author":"Broeder AA","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1111"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.034"},{"key":"e_1_2_13_61_1","volume-title":"Humira [Humira: EPAR \u2010 Product Information]","author":"European Medicines Agency","year":"2014"},{"key":"e_1_2_13_62_1","volume-title":"Otezla \u2010 Summary of product characteristics (Annex I). 08\/07\/2016 Otezla \u2010EMEA\/H\/C\/003746 \u2010PSUSA\/10338\/201506","author":"European Medicines Agency","year":"2016"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60642-4"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04716.x"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12448"},{"key":"e_1_2_13_68_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long\u2010term efficacy and safety of brodalumab in the treatment of psoriasis: 120\u2010week results from the randomized, double\u2010blind, placebo\u2010 and active comparator\u2010controlled phase 3 AMAGINE\u20102 trial","volume":"82","author":"Puig L","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00466-2"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.024"},{"key":"e_1_2_13_72_1","volume-title":"Summary of product characteristics Brodalumab","author":"European Medicines Agency"},{"key":"e_1_2_13_73_1","first-page":"s29","article-title":"What lies beneath the face value of a BOX WARNING: A deeper look at Brodalumab","volume":"17","author":"Hashim PW","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12042"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_2_13_79_1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7150\/jca.37015","article-title":"Risk of non\u2010melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta\u2010analysis","volume":"11","author":"Wang X","year":"2020","journal-title":"J Cancer"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.719"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.026"},{"key":"e_1_2_13_82_1","volume-title":"Fachinformation Enbrel 50 mg Fertigspritze","author":"Wyeth Europa Ltd","year":"2007"},{"key":"e_1_2_13_83_1","volume-title":"Taltz","author":"European Medicines Agency"},{"key":"e_1_2_13_84_1","volume-title":"Summary of product characteristics Ixekizumab","author":"European Medicines Agency","year":"2019"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14237"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153"},{"key":"e_1_2_13_87_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER\u20103 study","volume":"34","author":"Lebwohl MG","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_88_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjd.18550","article-title":"An indirect comparison of long\u2010term efficacy of every\u2010two\u2010week dosing versus recommended dosing of ixekizumab in patients who had sPGA>1 at week 12","volume":"183","author":"Papp K","year":"2019","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_89_1","volume-title":"Skyrizi \u2010 EMEA\/H\/C\/004759 \u2010 IA\/0006","author":"European Medicines Agency","year":"2019"},{"key":"e_1_2_13_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0730-x"},{"key":"e_1_2_13_91_1","volume-title":"Cosentyx \u2010 Summary of product characteristics (Annex I)","author":"European Medicines Agency","year":"2016"},{"key":"e_1_2_13_92_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_2_13_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_2_13_94_1","volume-title":"Secukinumab (AIN457) \u2010 ADVISORY COMMITTEE BRIEFING MATERIAL: AVAILABLE FOR PUBLIC RELEASE","author":"Novartis Pharmaceuticals Corporation","year":"2014"},{"key":"e_1_2_13_95_1","unstructured":"Swiss Specialist Information Ilumetri.2018."},{"key":"e_1_2_13_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"e_1_2_13_97_1","volume-title":"IlumetriTM (Tildrakizumab) Summary of product characteristics","author":"European Medicines Agency","year":"2019"},{"key":"e_1_2_13_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy491"},{"key":"e_1_2_13_99_1","volume-title":"Questions and answers on biosimilar medicines (similar biological medicinal products)","author":"European Medicines Agency","year":"2012"},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14605"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16915","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:47:40Z","timestamp":1693756060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/jdv.16915"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16915","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"2020-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}